venBio Partners LLC Makes New Investment in Lyell Immunopharma, Inc. $LYEL

venBio Partners LLC acquired a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 337,697 shares of the company’s stock, valued at approximately $4,744,643. Lyell Immunopharma comprises approximately 0.0% of venBio Partners LLC’s holdings, making the stock its 7th biggest holding. venBio Partners LLC owned about 1.38% of Lyell Immunopharma as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in shares of Lyell Immunopharma during the 2nd quarter worth about $347,000. Bank of America Corp DE increased its holdings in shares of Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after acquiring an additional 25,276 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Lyell Immunopharma by 194.8% in the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after purchasing an additional 76,921 shares during the period. Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma in the first quarter worth approximately $445,000. Finally, Dimensional Fund Advisors LP bought a new stake in Lyell Immunopharma in the 1st quarter worth about $959,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on LYEL shares. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research report on Friday, August 14th. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Zacks Research upgraded shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a research note on Friday, August 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Lyell Immunopharma currently has an average rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma Trading Down 0.5%

LYEL traded down $0.08 on Friday, hitting $14.53. 78,121 shares of the company’s stock were exchanged, compared to its average volume of 129,821. The firm has a 50-day moving average price of $13.85 and a 200-day moving average price of $18.02. Lyell Immunopharma, Inc. has a fifty-two week low of $10.76 and a fifty-two week high of $45.00. The stock has a market cap of $356.04 million, a price-to-earnings ratio of -1.13 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -7.2 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.